March 5, 2018 Clinical Research/Diagn.

QIAGEN launches CE-IVD assay to detect Trichomonas vaginalis in both female and male patients on the QIAsymphony RGQ platform

MAR 05 2018 New artus® assay enables detection of T. vaginalis from a broad range of sample types and expands sexually transmitted infection (STI) menu Germantown, Maryland, and Hilden, Germany, March 5th, 2018 – QIAGEN today announced the European launch of the artus T. vaginalis QS-RGQ Kit, a CE-marked molecular diagnostic test for the qualitative detection of the... Read more

March 5, 2018 Acad, Gov/Utilities Product Launch

QIAGEN launches CE-IVD assay to detect Trichomonas vaginalis in both female and male patients on the QIAsymphony RGQ platform

Germantown, Maryland, and Hilden, Germany, March 5th, 2018 – QIAGEN today announced the European launch of the artus T. vaginalis QS-RGQ Kit, a CE-marked molecular diagnostic test for the qualitative detection of the protozoan parasite T. vaginalis in both female and male patients. The artus T. vaginalis QS-RGQ Kit is an in vitro real-time polymerase... Read more

February 23, 2018 Uncategorized

QIAGEN opens Shared Services Center in Taguig City, Manila

MANILA, February 23, 2018 – QIAGEN N.V. today announced the opening of QIAGEN Business Services (QBS) Manila, its new Shared Service Center in the Philippines. The new location in the Cyber Sigma building in Fort Bonifacio, Taguig City, Manila, was officially opened today by Roland Sackers, Chief Financial Officer of QIAGEN, in a ceremony that... Read more

February 22, 2018 Chromatography Product Launch

QIAGEN welcomes WHO’s new global guidelines on latent TB screening

Germantown, Maryland, and Hilden, Germany, February 22th, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today endorsed new guidelines issued by the World Health Organization (WHO), which coordinates global efforts to control tuberculosis (TB), calling for harmonization of preventive screening and treatment of latent TB infection among vulnerable groups in countries with a... Read more

February 20, 2018 Chromatography Product Launch

QIAGEN welcomes new decision by U.S. Centers for Disease Control to use modern blood-based TB tests for immigration screening

Germantown, Maryland, and Hilden, Germany, February 20th, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it welcomed a decision by the U.S. Centers for Disease Control (CDC) to require the use of modern blood-based tests (IGRA) for tuberculosis (TB) screening. QIAGEN’s QuantiFERON-TB® Gold Plus (QFT-Plus®), the gold standard and market... Read more

February 9, 2018 Uncategorized

QIAGEN’s QuantiFERON-TB Gold Plus gains approval in Japan

Hilden, Germany, and Tokyo, Japan, February 8th, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Japan’s Ministry of Health Labor and Welfare has approved QuantiFERON®-TB Gold Plus (QFT®-Plus) as an in vitro diagnostic to detect tuberculosis (TB) infection. QFT-Plus is the fourth generation of QIAGEN’s market-leading QuantiFERON-TB technology, combining innovative... Read more

February 6, 2018 Product Launch

QIAGEN launches predictive therascreen PITX2 test in Europe to guide treatment in high-risk breast cancer

Hilden, Germany, February 6th , 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the European launch of its novel therascreen PITX2 RGQ PCR Kit, the first clinically validated DNA methylation assay that helps predict the response of certain high-risk breast cancer patients to anthracycline-based chemotherapy. The CE-IVD marked assay is QIAGEN’s... Read more

February 6, 2018 M&A, Partnerships Microscopy

QIAGEN and DiaSorin partner to offer fully automated tuberculosis detection with QuantiFERON-TB Gold Plus available on LIAISON analyzer systems

QIAGEN’s QuantiFERON-TB customers to gain access to fully automated workflow solution DiaSorin to add novel content to already broad LIAISON menu, over 7,000 systems installed QIAGEN announces milestone of over 40 million QuantiFERON-TB tests since launch January 8, 2018 – Saluggia, Italy; Hilden, Germany, and Germantown, Maryland – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Stock Exchange:... Read more

February 5, 2018 Licensing, IP, and Legal Liq. Handling & Robotics M&A, Partnerships

QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing

Germantown, Maryland, and Hilden, Germany, January 31, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today it has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR... Read more